Topiramate dose effects on cognition: A randomized double-blind study

Neurology

Volumn 76, Issue 2, 2011, Pages 131-137

  Loring, D W ^a,b   Williamson, D J ^d   Meador, K J ^a   Wiegand, F ^b   Hulihan, J ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOPIRAMATE;

ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; ANTICONVULSANTS; BODY MASS INDEX; BODY WEIGHT; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78751608234     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318206ca02     Document Type: Article

References (11)

1. Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev 2007;17:413-425.
2. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obesity Res 2003;11:722-733.
3. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991;59:12-19.
4. Veroff AE, Bodick NC, Offen WW, et al. Efficacy of xa-nomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord 1998;12:304-312.
5. Cutler NR, Shrotriya RC, Sramek JJ, et al. The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease. Ann NY Acad Sci 1993;695:332-336.
6. Veroff AE, Cutler NR, Sramek JJ, et al. A new assessment tool for neuropsychopharmacologic research: the Computerized Neuropsychological Test Battery. J Geriatr Psychiatry Neurol 1991;4:211-217.
7. Cutler NR, Veroff AE, Frackiewicz EJ, et al. Assessing the neuropsychological profile of stable schizophrenic outpatients. J Neuropsychiatry Clin Neurosci 1996;8:423-428.
8. Brass EP, Polinsky R, Sramek JJ, et al. Effects of the choli-nomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans. J Clin Psychopharmacol 1995;15:58-62.
9. Meador KJ, Loring DW, Hulihan JF, et al. Differential cognitive and behavioral effects of topiramate and val-proate. Neurology 2003;60:1483-1488.
10. Chelune GJ, Naugle RI, Lüders H, et al. Individual change after epilepsy surgery: practice effects and base-rate information. Neuropsychology 1993;7:41-52.
11. Johannessen SI, Patsalos PN, Tomson T, Perucca E. Therapeutic drug monitoring. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook, vol 2, 2nd ed. New York: Lippincott Williams & Wilkins; 2008: 1171-1183.